Peptomyc, a CataloniaBio & HealthTech member, announces it has appointed Dr Manuela Niewel as Chief Medical Officer (CMO). Niewel will assume responsibility for leading Peptomyc’s overall clinical development, regulatory and medical affairs activities.
Peptomyc is currently completing its pre-clinical safety studies with OMO103, its first-in-class peptide compound against MYC, an oncoprotein deregulated in most types of cancer. OMO103 has demonstrated its anti-tumor activity in multiple mouse models.
“We are convinced that Manuela’s deep experience in patients, innovative drug development and regulatory strategy will contribute to the successful implementation of our clinical trials in 2020” says Laura Soucek and Marie-Eve Beaulieu, co-founders of the company.
Related news: Peptomyc gets €2.2 million through SME Instrument
Comments